Key facts
- Notable investors include Changxing Fund, Peak Valley Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Rongrui Pharmaceutical Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Rongrui Pharmaceutical Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rongrui Pharmaceutical Technology
Developer of oncolytic virus-based immunotherapies intends to provide innovative treatments for cancer patients. The company's platforms are characterized by proprietary OVV-Drive-IO technology, including Adaptive Cell Transfer (ACT) and antibody-based combination therapies.
- Sector
- Healthcare
- HQ
- Zhaoyang, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Rongrui Pharmaceutical Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rongrui Pharmaceutical Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rongrui Pharmaceutical Technology in its N-PORT filings yet. We sweep new filings monthly.